.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Dow
Harvard Business School
Federal Trade Commission
Johnson and Johnson
Boehringer Ingelheim
Chinese Patent Office
AstraZeneca
Merck
Covington

Generated: June 27, 2017

DrugPatentWatch Database Preview

XALATAN Drug Profile

« Back to Dashboard

What is the patent landscape for Xalatan, and what generic Xalatan alternatives are available?

Xalatan is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in XALATAN is latanoprost. There are nineteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

Summary for Tradename: XALATAN

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list36
Clinical Trials: see list65
Patent Applications: see list2,490
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:XALATAN at DailyMed

Pharmacology for Tradename: XALATAN

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
XALATAN
latanoprost
SOLUTION/DROPS;OPHTHALMIC020597-001Jun 5, 1996ATRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: XALATAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn
XALATAN
latanoprost
SOLUTION/DROPS;OPHTHALMIC020597-001Jun 5, 19966,429,226► Subscribe
Pharmacia And Upjohn
XALATAN
latanoprost
SOLUTION/DROPS;OPHTHALMIC020597-001Jun 5, 19964,599,353► Subscribe
Pharmacia And Upjohn
XALATAN
latanoprost
SOLUTION/DROPS;OPHTHALMIC020597-001Jun 5, 19965,422,368► Subscribe
Pharmacia And Upjohn
XALATAN
latanoprost
SOLUTION/DROPS;OPHTHALMIC020597-001Jun 5, 19967,163,959► Subscribe
Pharmacia And Upjohn
XALATAN
latanoprost
SOLUTION/DROPS;OPHTHALMIC020597-001Jun 5, 19965,296,504► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Fuji
Baxter
Daiichi Sankyo
McKinsey
US Department of Justice
AstraZeneca
US Army
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot